ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,625,810 | -21.1% | 1,083,287 | +2.1% | 0.01% | -16.7% |
| Q2 2023 | $48,926,107 | +20.2% | 1,060,613 | +4.5% | 0.01% | +20.0% |
| Q1 2023 | $40,687,092 | +89237.8% | 1,014,640 | +3.2% | 0.01% | -16.7% |
| Q4 2022 | $45,543 | -99.9% | 983,030 | +6.3% | 0.01% | 0.0% |
| Q3 2022 | $38,299,000 | -29.4% | 924,877 | +1.8% | 0.01% | -25.0% |
| Q2 2022 | $54,213,000 | -17.3% | 908,713 | +0.6% | 0.01% | 0.0% |
| Q1 2022 | $65,568,000 | -11.1% | 902,900 | +3.0% | 0.01% | -11.1% |
| Q4 2021 | $73,743,000 | -3.4% | 876,956 | +3.7% | 0.01% | -10.0% |
| Q3 2021 | $76,306,000 | -1.8% | 846,067 | +3.8% | 0.01% | -9.1% |
| Q2 2021 | $77,729,000 | -36.6% | 815,199 | -24.3% | 0.01% | -42.1% |
| Q1 2021 | $122,574,000 | -9.4% | 1,076,533 | +10.2% | 0.02% | -17.4% |
| Q4 2020 | $135,248,000 | +91.6% | 977,019 | +13.8% | 0.02% | +64.3% |
| Q3 2020 | $70,584,000 | +5.2% | 858,797 | +0.1% | 0.01% | 0.0% |
| Q2 2020 | $67,097,000 | +84.9% | 857,802 | +5.0% | 0.01% | +55.6% |
| Q1 2020 | $36,298,000 | -42.9% | 816,975 | -45.2% | 0.01% | +28.6% |
| Q4 2019 | $63,624,000 | +103.3% | 1,489,710 | +103.6% | 0.01% | 0.0% |
| Q3 2019 | $31,301,000 | -31.9% | 731,679 | +1.0% | 0.01% | -36.4% |
| Q2 2019 | $45,992,000 | -1.2% | 724,289 | +7.9% | 0.01% | -8.3% |
| Q1 2019 | $46,556,000 | -5.8% | 671,246 | -40.9% | 0.01% | +50.0% |
| Q4 2018 | $49,412,000 | +28.1% | 1,136,460 | +125.0% | 0.01% | -27.3% |
| Q3 2018 | $38,560,000 | +4.6% | 505,112 | +5.3% | 0.01% | 0.0% |
| Q2 2018 | $36,860,000 | +66.2% | 479,514 | +10.2% | 0.01% | +57.1% |
| Q1 2018 | $22,184,000 | +31.7% | 435,072 | +19.8% | 0.01% | +16.7% |
| Q4 2017 | $16,844,000 | -13.0% | 363,190 | -0.1% | 0.01% | -14.3% |
| Q3 2017 | $19,365,000 | -10.5% | 363,609 | +4.4% | 0.01% | -22.2% |
| Q2 2017 | $21,629,000 | -4.4% | 348,239 | +4.3% | 0.01% | 0.0% |
| Q1 2017 | $22,619,000 | +7.7% | 333,724 | +11.7% | 0.01% | -10.0% |
| Q4 2016 | $21,006,000 | +8.0% | 298,768 | +8.9% | 0.01% | 0.0% |
| Q3 2016 | $19,454,000 | +51.1% | 274,239 | +4.2% | 0.01% | +42.9% |
| Q2 2016 | $12,873,000 | -21.1% | 263,221 | +2.1% | 0.01% | -22.2% |
| Q1 2016 | $16,315,000 | -41.3% | 257,713 | +4.0% | 0.01% | -43.8% |
| Q4 2015 | $27,789,000 | +21.5% | 247,726 | +4.3% | 0.02% | +14.3% |
| Q3 2015 | $22,867,000 | +18.0% | 237,439 | +25.4% | 0.01% | +27.3% |
| Q2 2015 | $19,382,000 | +123.2% | 189,299 | +35.4% | 0.01% | +120.0% |
| Q1 2015 | $8,683,000 | +61.1% | 139,849 | +13.8% | 0.01% | +66.7% |
| Q4 2014 | $5,391,000 | -23.9% | 122,864 | -1.8% | 0.00% | -40.0% |
| Q3 2014 | $7,083,000 | +329.5% | 125,156 | +240.7% | 0.01% | +400.0% |
| Q2 2014 | $1,649,000 | -6.2% | 36,740 | +2.2% | 0.00% | 0.0% |
| Q1 2014 | $1,758,000 | – | 35,962 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |